Research programme: oncolytic vaccinia viruses - SillaJen BiotherapeuticsAlternative Names: JX-963; SJ 815; SJ 963
Latest Information Update: 27 Jun 2014
At a glance
- Originator Jennerex Biotherapeutics
- Developer Jennerex
- Class Oncolytic viruses
- Mechanism of Action Epidermal growth factor receptor antagonists; Ras signal transduction pathway inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer